Non-Rx drug exclusion from Canadian patented drug price controls bill sought by NDMAC.
This article was originally published in The Tan Sheet
Executive Summary
CANADIAN NON-Rx DRUG EXCLUSION FROM BILL C-91 SOUGHT BY NDMAC in a brief submitted March 27 to the Parliamentary Committee on Industry. The committee is reviewing Bill C-91, a 1993 act amending Canada's patent laws by establishing a Patented Medicine Prices Review Board (PMPRB) to set price controls for patented drugs, both prescription and nonprescription. Although the bulk of patented drugs in Canada are prescription, there is a movement under way in the country to expand the board's jurisdiction to nonpatented drugs, which would affect an additional 8,000-10,000 non-Rx products.
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning